Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.43 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24729176 | 0.88 | L3MBTL1 (0.66) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL5225753 | 0.86 | L3MBTL1 (0.67) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL1520892 | 0.86 | L3MBTL1 (0.70) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL10088115 | 0.86 | L3MBTL1 (0.74) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL12572728 | 0.85 | L3MBTL1 (0.73) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL7505969 | 0.84 | L3MBTL1 (0.65) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL30777140 | 0.84 | L3MBTL1 (0.72) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL29992401 | 0.84 | L3MBTL1 (0.65) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL22153097 | 0.84 | L3MBTL1 (0.67) | L3MBTL1EPHX1HTR6PDE10AACHE | |
| SCHEMBL23522089 | 0.84 | L3MBTL1 (0.67) | L3MBTL1EPHX1HTR6PDE10AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | L3MBTL1 2099/4885EPHX1 1507/4885HTR6 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.